APA (7th ed.) Citation

MacDonald, V., Lee, X. Y., Caillaud, A., Luckevich, M., & Bentley, A. (2020). Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch. Blood, 136(Supplement 1), 19. https://doi.org/10.1182/blood-2020-134236

Chicago Style (17th ed.) Citation

MacDonald, Vance, Xin Ying Lee, Alexandre Caillaud, Maria Luckevich, and Anthony Bentley. "Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch." Blood 136, no. Supplement 1 (2020): 19. https://doi.org/10.1182/blood-2020-134236.

MLA (9th ed.) Citation

MacDonald, Vance, et al. "Estimation of the Impact on Treatment Costs of a Switch to Nonacog Beta Pegol (N9-GP) for the Treatment of Adults with Hemophilia B in Canada Based on Real-World Factor IX (FIX) Consumption and Clinical Outcomes Pre- and Post-Switch." Blood, vol. 136, no. Supplement 1, 2020, p. 19, https://doi.org/10.1182/blood-2020-134236.